Aveo Pharmaceuticals Inc. (Nasdaq: AVEO) has launched a Phase 2 trial to test its cancer drug candidate tivozanib, in combination with the approved drug Avastin, in patients with colorectal cancer. The drug candidate is also being tested in a Phase 3 trial for patients with advanced renal cell carcinoma.
This new trial, called BATON-CRC, is part of a series of trials designed to discover whether tivozanib could work especially well in patients with certain genetic biomarkers, and it is being led by Aveo?s Japanese partner Astellas Pharma Inc. It has begun enrolling participants and plans to include approximately 252 patients at about 80 centers in the U.S., Canada, Australia and Europe.
?BATON-CRC is further example of Aveo?s commitment to patient care and advancing the science behind biomarkers,? Aveo Chief Medical Officer Dr. William Slichenmyer said in a statement. ?The identification and development of relevant biomarkers through our Human Response Platform is a core component of our oncology drug development efforts. We plan to use biomarker data from BATON-CRC and BATON-RCC to inform our clinical development strategy in an effort to bring tivozanib to the patients who will benefit most.?
The American Cancer Society estimates that more than 140,000 men and women in the U.S. will be diagnosed with colorectal cancer and nearly 50,000 will die of the disease in the U.S.
?
?
ny jets seahawks new york giants dallas cowboys giants denver broncos patriots
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.